The United States of America, As Represented by the Secretary, Department of Health and Human Services

Research Triangle Institute

Biogen Ma Inc.

Rafal Kaminski

Scott P Runyon

John A Kepler

Hernan A Navarro

Michael A Rogawski

Matthew Orr

Edgar Cook

Margaret S Lee

Marc Roger De Ryck

Sharon Tamir

Benoit Kenda

Karine Leclercq

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, of Formula (I) for treating epilepsy in a subject. Subjects can have unprovoked seizures without prior warning that affect one or both hemispheres of the brain. The disclosed methods can reduce the severity and occurrence of these unprovoked epileptic seizures and can result in resolution of epilepsy. The method comprises administering to the subject an effective amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. 

CRM1 inhibitors for treating epilepsy

This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage. 

Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.

Growing community of inventors

Waterloo, Belgium

Rafal Kaminski